Black Diamond Therapeutics Financial Statements (BDTX)
|
|
|
|
Report date
|
|
|
17.03.2022 |
09.03.2023 |
12.03.2024 |
06.03.2025 |
16.03.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
70.0 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-126.9 |
-92.8 |
-86.5 |
-78.8 |
19.9 |
|
-53.3 |
|
EBITDA, bln rub |
? |
|
-126.7 |
-92.3 |
-86.0 |
-78.4 |
20.2 |
|
-40.3 |
|
Net profit, bln rub |
? |
|
-125.6 |
-91.2 |
-82.4 |
-69.7 |
22.4 |
|
-43.2 |
|
|
OCF, bln rub |
? |
|
-100.1 |
-85.1 |
-66.7 |
-62.3 |
29.6 |
|
-34.0 |
|
CAPEX, bln rub |
? |
|
2.71 |
0.192 |
0.033 |
0.000 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-102.9 |
-85.3 |
-66.8 |
-62.3 |
29.6 |
|
-34.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
126.9 |
92.8 |
86.0 |
78.8 |
49.8 |
|
53.2 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.437 |
0.000 |
0.325 |
|
0.113 |
|
R&D, bln rub |
|
|
96.8 |
64.4 |
58.9 |
51.3 |
33.6 |
|
30.1 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
247.7 |
156.3 |
158.6 |
122.6 |
143.0 |
|
132.9 |
|
Net Assets, bln rub |
? |
|
195.9 |
115.7 |
116.7 |
83.3 |
112.2 |
|
104.3 |
|
Debt, bln rub |
|
|
28.5 |
28.1 |
25.3 |
22.2 |
15.1 |
|
17.9 |
|
Cash, bln rub |
|
|
209.8 |
122.8 |
131.4 |
98.6 |
128.7 |
|
118.3 |
|
Net debt, bln rub |
|
|
-181.3 |
-94.7 |
-106.1 |
-76.4 |
-113.6 |
|
-100.4 |
|
|
Ordinary share price, rub |
|
|
5.33 |
|
|
2.14 |
2.43 |
|
2.13 |
|
Number of ordinary shares, mln |
|
|
36.2 |
36.2 |
44.0 |
55.0 |
56.9 |
|
57.2 |
|
|
Market cap, bln rub |
|
|
193 |
0 |
0 |
118 |
138 |
|
122 |
|
EV, bln rub |
? |
|
12 |
-95 |
-106 |
41 |
25 |
|
22 |
|
Book value, bln rub |
|
|
196 |
116 |
117 |
83 |
112 |
|
104 |
|
|
EPS, rub |
? |
|
-3.47 |
-2.52 |
-1.88 |
-1.27 |
0.39 |
|
-0.75 |
|
FCF/share, rub |
|
|
-2.84 |
-2.35 |
-1.52 |
-1.13 |
0.52 |
|
-0.59 |
|
BV/share, rub |
|
|
5.41 |
3.19 |
2.66 |
1.51 |
1.97 |
|
1.82 |
|
|
EBITDA margin, % |
? |
|
|
|
|
|
28.9% |
|
|
|
Net margin, % |
? |
|
|
|
|
|
32.0% |
|
|
|
FCF yield, % |
? |
|
-53.3% |
|
|
-52.9% |
21.4% |
|
-27.9% |
|
ROE, % |
? |
|
-64.1% |
-78.8% |
-70.6% |
-83.7% |
19.9% |
|
-41.4% |
|
ROA, % |
? |
|
-50.7% |
-58.3% |
-52.0% |
-56.8% |
15.6% |
|
-32.5% |
|
|
P/E |
? |
|
-1.54 |
0.00 |
0.00 |
-1.69 |
6.18 |
|
-2.82 |
|
P/FCF |
|
|
-1.88 |
0.00 |
0.00 |
-1.89 |
4.67 |
|
-3.58 |
|
P/S |
? |
|
|
|
|
|
1.97 |
|
|
|
P/BV |
? |
|
0.98 |
0.00 |
0.00 |
1.41 |
1.23 |
|
1.17 |
|
EV/EBITDA |
? |
|
-0.09 |
1.03 |
1.23 |
-0.53 |
1.22 |
|
-0.53 |
|
Debt/EBITDA |
|
|
1.43 |
1.03 |
1.23 |
0.97 |
-5.62 |
|
2.49 |
|
|
R&D/CAPEX, % |
|
|
3 573% |
33 561% |
178 524% |
|
|
|
|
|
|
CAPEX/Revenue, % |
|
|
|
|
|
|
0.00% |
|
|
|
| Black Diamond Therapeutics shareholders |
